SHILPAMED Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shilpa Medicare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹813.15 |
| 52 Week High | ₹959.50 |
| 52 Week Low | ₹313.15 |
| Beta | 0.69 |
| 1 Month Change | -7.61% |
| 3 Month Change | -6.17% |
| 1 Year Change | 124.63% |
| 3 Year Change | 49.56% |
| 5 Year Change | 182.39% |
| Change since IPO | 1,171.21% |
Recent News & Updates
Recent updates
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You
Sep 12
Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues
Jul 05What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You
Apr 12Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt
Jan 02These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively
Jul 17Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt
Mar 17Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)
Sep 22Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Sep 07Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Aug 14Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load
Jan 27Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why
Sep 21Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jun 17If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late
May 31Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 07Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year
Feb 20Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jan 26
Shareholder Returns
| SHILPAMED | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.2% | 1.8% | -2.1% |
| 1Y | 124.6% | 43.7% | 22.5% |
Return vs Industry: SHILPAMED exceeded the Indian Pharmaceuticals industry which returned 43.7% over the past year.
Return vs Market: SHILPAMED exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility
| SHILPAMED volatility | |
|---|---|
| SHILPAMED Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: SHILPAMED has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SHILPAMED's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,007 | Vishnukanth Bhutada | www.vbshilpa.com |
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate.
Shilpa Medicare Limited Fundamentals Summary
| SHILPAMED fundamental statistics | |
|---|---|
| Market cap | ₹71.96b |
| Earnings (TTM) | ₹610.83m |
| Revenue (TTM) | ₹12.16b |
115.7x
P/E Ratio5.8x
P/S RatioIs SHILPAMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHILPAMED income statement (TTM) | |
|---|---|
| Revenue | ₹12.16b |
| Cost of Revenue | ₹4.45b |
| Gross Profit | ₹7.72b |
| Other Expenses | ₹7.11b |
| Earnings | ₹610.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.04 |
| Gross Margin | 63.45% |
| Net Profit Margin | 5.02% |
| Debt/Equity Ratio | 21.1% |
How did SHILPAMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 13:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shilpa Medicare Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Harith Ahamed | Avendus Spark |
| Prathamesh Masdekar | BP Wealth Management Private Limited |